comprehensive -WSS

comprehensive

author：hotspot 2025-09-03 03:29:59 - browse：5616

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Feds fine Medicare Advantage plans for overcharging members

WSS

What do new weight loss drugs mean for bariatric surgery?

Psilocybin's anti

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

UnitedHealth wins $3.3 billion takeover of Amedisys

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Wikipedia

comprehensive

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Drug firms test therapies to halt Alzheimer’s before symptoms arise

How one medical school became remarkably diverse

What AAP's gender

Dobbs anniversary: the lost opportunity of abortion as health care

In science, is the line between industry and academia shifting?

The high cost of giving birth even with insurance

How a symptom of dementia informs our understanding of creativity

Virginia high school admissions case could be legal follow

2024 GOP presidential candidates spar over abortion in debate

leisure time

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Eating disorder hotline's move to chatbot carried cost for volunteers

Radiation, mainstay of cancer treatment, begins a fade

How to make Best Hospitals ratings actually useful for patients

knowledge

leisure time

focus

hotspot